Zacks Research Issues Optimistic Forecast for EHC Earnings

Encompass Health Co. (NYSE:EHC - Free Report) - Equities research analysts at Zacks Research increased their Q2 2025 earnings per share estimates for shares of Encompass Health in a report released on Wednesday, May 7th. Zacks Research analyst R. Sipani now anticipates that the company will earn $1.17 per share for the quarter, up from their prior estimate of $1.16. The consensus estimate for Encompass Health's current full-year earnings is $4.80 per share. Zacks Research also issued estimates for Encompass Health's Q3 2025 earnings at $1.16 EPS, FY2025 earnings at $4.94 EPS, Q1 2026 earnings at $1.31 EPS and FY2026 earnings at $5.20 EPS.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $1.37 EPS for the quarter, topping the consensus estimate of $1.19 by $0.18. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The company's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.12 earnings per share.

A number of other analysts also recently commented on the company. Truist Financial reaffirmed a "buy" rating and set a $135.00 price target (up from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. Barclays increased their price objective on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a report on Friday, April 25th. William Blair reissued an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. KeyCorp increased their price objective on Encompass Health from $120.00 to $122.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Finally, Royal Bank of Canada lifted their price target on Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a research report on Monday, April 28th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Encompass Health presently has an average rating of "Buy" and a consensus target price of $120.86.

Encompass Health Stock Up 1.5%

Shares of Encompass Health stock traded up $1.71 on Monday, hitting $119.32. The company had a trading volume of 1,195,426 shares, compared to its average volume of 689,788. The stock has a market capitalization of $12.03 billion, a price-to-earnings ratio of 26.75, a P/E/G ratio of 2.31 and a beta of 0.91. Encompass Health has a 1 year low of $82.74 and a 1 year high of $120.60. The stock has a 50 day moving average of $104.14 and a 200-day moving average of $100.28. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of EHC. Miracle Mile Advisors LLC grew its holdings in shares of Encompass Health by 3.0% during the 4th quarter. Miracle Mile Advisors LLC now owns 3,835 shares of the company's stock worth $354,000 after acquiring an additional 112 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in shares of Encompass Health by 19.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 720 shares of the company's stock worth $73,000 after purchasing an additional 115 shares in the last quarter. US Bancorp DE boosted its position in shares of Encompass Health by 9.6% in the 4th quarter. US Bancorp DE now owns 1,380 shares of the company's stock worth $127,000 after purchasing an additional 121 shares in the last quarter. Signaturefd LLC lifted its position in Encompass Health by 21.6% in the 4th quarter. Signaturefd LLC now owns 704 shares of the company's stock valued at $65,000 after acquiring an additional 125 shares in the last quarter. Finally, Arlington Trust Co LLC lifted its position in Encompass Health by 22.9% in the 1st quarter. Arlington Trust Co LLC now owns 671 shares of the company's stock valued at $68,000 after acquiring an additional 125 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company's stock.

Insider Activity at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the transaction, the chief accounting officer now owns 69,164 shares in the company, valued at approximately $6,798,129.56. The trade was a 6.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP John Patrick Darby sold 10,000 shares of Encompass Health stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total value of $1,147,900.00. Following the completion of the transaction, the executive vice president now owns 79,710 shares in the company, valued at approximately $9,149,910.90. This represents a 11.15% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 19,321 shares of company stock valued at $2,142,452. Company insiders own 2.00% of the company's stock.

Encompass Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.57%. The ex-dividend date is Tuesday, July 1st. Encompass Health's dividend payout ratio is 14.05%.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.